NCT07035249招募中1 期
A Prospective, Single-Arm Clinical Trial Evaluating DCSZ11 Combined With Standard-of-Care Therapy in Patients With Advanced or Metastatic Solid Tumors
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
To evaluate the safety and efficacy of DCSZ11 in combination with standard therapy in patients with advanced or metastatic solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients aged ≥18 years.
- •Willing and able to provide written informed consent for the study.
- •Patients with histologically confirmed advanced or metastatic solid tumors. Note: Patients must have guideline-eligible standard chemotherapy and immunotherapy options available.Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) must have PD-L1 Combined Positive Score (CPS) ≥1.Lung cancer patients with known actionable driver gene mutations/genomic aberrations (e.g., EGFR sensitizing mutations, BRAF V600E mutation, ROS1 rearrangements, NTRK gene fusions, ALK rearrangements) are excluded.Prior adjuvant or neoadjuvant chemotherapy is permitted, provided ≥6 months have elapsed between the last dose of chemotherapy/immunotherapy and documented recurrent disease.Gastric cancer patients must be HER2-negative.
- •Patients must have at least one measurable lesion per RECIST 1.1 criteria. Lesions located in previously irradiated areas may be considered measurable if there is objective evidence of progression in those lesions prior to study enrollment.
- •Patients with previously treated central nervous system (CNS) metastases are eligible provided they meet all the following criteria:
- •Stability (i.e., no evidence of progression on magnetic resonance imaging [MRI]) for ≥4 weeks prior to the first dose of study drug, and
- •All neurological symptoms have returned to baseline, and
- •No requirement for steroid therapy for at least 14 days prior to the first dose of study intervention.
- •Patients with signs or symptoms suggestive of CNS metastases must undergo brain imaging within 2 weeks prior to the first dose of study drug to confirm the absence of detectable CNS disease.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Adequate organ function and bone marrow reserve per laboratory assessments within 10 days prior to first study drug administration:
- •Bone marrow function:
- •Absolute neutrophil count (ANC) ≥1,500/µL
- •Hemoglobin ≥9 g/dL (must be achieved without erythropoietin dependency AND without packed red blood cell [pRBC] transfusion within the preceding 2 weeks)
- •Platelet count ≥100,000/µL
- •Hepatic function:
- •Total serum bilirubin ≤1.5 × upper limit of normal (ULN); or direct bilirubin ≤ULN for patients with total bilirubin >1.5 × ULN
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (≤5 × ULN if liver metastases present)
- •Renal function:
- •Estimated creatinine clearance ≥30 mL/min (per Cockcroft-Gault formula)
- •PD-L1 status must be available for all patients via approved immunohistochemistry assay.
- •Resolution of all prior treatment-related toxicities to Grade ≤1 or baseline, or determination as irreversible sequelae.
- •*Note: Grade ≤2 neuropathy and/or hearing loss, alopecia of any grade, or autoimmune endocrinopathies on stable replacement therapy are permitted.*
- •Female patients must agree to refrain from breastfeeding for 5 months after last study dose and satisfy one of:
- •Postmenopausal for ≥1 year prior to screening, or
- •Surgically sterile, or
- •Agreement to use one highly effective contraceptive method plus one additional barrier method from signing informed consent form (ICF) until 5 months after last study dose, or
- •Practice true abstinence* when consistent with preferred lifestyle Periodic abstinence, withdrawal, spermicide-only, or lactational amenorrhea are unacceptable. Female/male condoms must not be used concomitantly.
- •Male patients, even surgically sterilized (i.e., post-vasectomy), must agree to either:
- •Use effective barrier contraception from ICF signing until 2 months after last DCSZ11 dose, or
- •Practice true abstinence* when consistent with preferred lifestyle Exclusions as per Criterion
- •Willingness and ability to comply with scheduled visits and procedures per protocol.
排除标准
- •Systemic anticancer therapy or investigational products within 6 months prior to first study dose.
- •*Note: Low-dose corticosteroids (oral prednisolone ≤10 mg daily or equivalent) and therapy with bisphosphonates or RANK ligand (RANKL) inhibitors are permitted.*
- •Extensive radiotherapy (RT) ≤6 months prior to treatment initiation (*≤7 days for palliative local RT outside chest/brain*) OR unresolved RT-related toxicity requiring corticosteroids.
- •Second primary malignancy within 3 years, except:
- •Adequately treated basal cell/locally confined squamous skin cancer Localized prostate cancer Carcinoma in situ of cervix/breast Resected colorectal adenomatous polyps Other malignancies not requiring active anticancer therapy.
- •Known active CNS metastases and/or carcinomatous meningitis.
- •Major surgery within 4 weeks or minor surgery within 2 weeks prior to first dose.
- •All wounds must be fully healed without infection/dehiscence, with full recovery and no ongoing surgical complications.
- •Known hypersensitivity to any component of the study drug(s).
- •Prior immunotherapy discontinued due to:
- •Grade ≥3 immune-related adverse events (irAEs) (except endocrinopathies controlled with replacement) Grade 2 myocarditis OR recurrent Grade 2 pneumonitis.
- •Active autoimmune disease requiring systemic immunosuppression within 2 years. Exempt: Physiologic hormone replacement (thyroxine, insulin, corticosteroids for adrenal/pituitary insufficiency).
- •Immunodeficiency diagnosis OR chronic systemic steroids (>10 mg prednisolone-equivalent/day) or other immunosuppressants within 7 days prior to first dose.
- •History of lung RT >30 Gy within 6 months prior to treatment.
- •History of (non-infectious) pneumonitis/interstitial lung disease (ILD) requiring steroids OR current pneumonitis/ILD.
- •History of allogeneic tissue/solid organ transplantation.
- •Live/live-attenuated vaccines within 4 weeks prior to treatment initiation. Inactivated vaccines permitted.
- •Active infection requiring systemic therapy.
- •Hepatitis B surface antigen (HBsAg)-positive with detectable HBV DNA.
- •Hepatitis C virus (HCV) infection with detectable HCV RNA at screening.
- •History within ≤6 months prior to first dose of:
- •NYHA Class III/IV congestive heart failure
- •Unstable angina
- •Myocardial infarction
- •Symptomatic ischemic heart disease
- •Uncontrolled hypertension despite optimal therapy
- •Persistent symptomatic arrhythmia >Grade 2
- •Pericardial effusion/restrictive cardiomyopathy. Permitted: Chronic atrial fibrillation on stable anticoagulation.
- •Any condition compromising informed consent, confounding results, or limiting protocol compliance-including medical/psychiatric/social factors-that, per investigator judgment, contraindicates participation.
- •Pregnant or lactating females.
研究组 & 干预措施
Low Dose
Experimental
DCSZ11 at Low Dose in combination with the available standard treatment.
干预措施: Low Dose DCSZ11 (Drug)
Low Dose
Experimental
DCSZ11 at Low Dose in combination with the available standard treatment.
干预措施: Standard Treatment (Drug)
Medium Dose
Experimental
DCSZ11 at Medium Dose in combination with the available standard treatment.
干预措施: Medium Dose DCSZ11 (Drug)
Medium Dose
Experimental
DCSZ11 at Medium Dose in combination with the available standard treatment.
干预措施: Standard Treatment (Drug)
High Dose
Experimental
DCSZ11 at High Dose in combination with the available standard treatment.
干预措施: High Dose DCSZ11 (Drug)
High Dose
Experimental
DCSZ11 at High Dose in combination with the available standard treatment.
干预措施: Standard Treatment (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: 2 years
The ratio of participants assessed with complete response (CR) or partial response(PR) as a best overall response.
次要结局
- Disease Control Rate (DCR)(2 years)
- DRR (Durable Response Rate)(2 years)
- DOR (Duration of Response)(2 years)
- TTR (Response Time）(2 years)
- PFS (progression-free survival)(2 years)
- OS (Overall Survival)(2 years)
- TTP (Time to Progression)(2 years)
研究者
Xingchen Peng
PhD，professor
West China Hospital
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT05765851Daiichi Sankyo108
撤回
不适用
Safety and Efficacy of SDX-3101 for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)Chronic Rhinosinusitis Without Nasal PolypsNCT04158596SynDermix AG
已完成
1 期
Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19COVID-19NCT04684446R-Pharm100
Unknown
1 期
A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal CancerColorectal Neoplasms MalignantNCT03993626Celleron Therapeutics Ltd.55
招募中
1 期
Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ PatiensHER2-positive Gastric CancerHER2-positive Gastroesophageal Junction AdenocarcinomaNCT06572319Zhejiang Cancer Hospital35